Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Shranjeno v:
Autoren: | , , , , , , , , , , , , , |
---|---|
Format: | Artikel |
Jezik: | angleščina |
Izdano: |
Philipps-Universität Marburg
2023
|
Teme: | |
Online dostop: | PDF-Volltext |
Oznake: |
Označite
Brez oznak, prvi označite!
|
No abstracts were found for this record.